Articles

Obinutuzumab plus Bendamustine in Previously Untreated Patients with CLL: Subgroup Analysis of the Phase 3 GREEN Study

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Phase 2 Study

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Ibrutinib versus Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle-Cell Lymphoma (MCL)

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Syk Inhibitor Entospletinib Monotherapy in CLL/SLL: Phase 2 Trial Results

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Outcomes of Ibrutinib Treatment in Patients with Relapsed or Refractory CLL/SLL with del17p in the RESONATE-17 Study

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Idelalisib plus Bendamustine/Rituximab versus Bendamustine/Rituximab in Relapsed/Refractory CLL: Results of a Phase 3 Study

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Rituximab, Lenalidomide, and Ibrutinib as Frontline Therapy in Follicular Lymphoma: Results of the ALLIANCE 051103 Phase 1 Study

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Results from the REVEL Trial: Exposure-Response Relationship for Ramucirumab plus Docetaxel vs Docetaxel as Second-line Treatment of Metastatic NSCLC

ASCO 2015 – Lung Cancer

Phase 3 Trial (Checkmate 057) of Nivolumab (NIVO) Versus Docetaxel (DOC) In Advanced Non Squamous Cell (Non-SQ) NSCLC

ASCO 2015 – Lung Cancer

A Phase 3B/4 Safety Trial of Nivolumab (NIVO) in Patients with Advanced or Metastatic NSCLC

ASCO 2015 – Lung Cancer

Page 128 of 143